Navigation Links
Daytrana in Medical News

New analysis shows DAYTRANA offered ADHD symptom control for 12 months

Washington, D.C. May 7, 2008 Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced findings from a new data analysis that was conducted to examine treatment differences with DAYTRANA (methylphenidate transdermal system) between boys and girls aged 6...

Long-term 12-month safety data on ADHD patch DAYTRANA

BOSTON OCTOBER 25, 2007 Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, announced that data from a 12-month study of DAYTRANATM (methylphenidate transdermal system), the Attention Deficit Hyperactivity Disorder (ADHD) patch, demonstrated that DAYTRA...

Shire Developed DAYTRANA – The First Medication to Treat ADHD Symptom

DAYTRANA (methylphenidate transdermal system), formulated by Shire was the foremost patch medication approved to treat symptoms of ADHD in children//. Transdermal formulation of methylphenidate - DAYTRANA, is now available in pharmacies in varying doses such as 10 mg, 15 mg, 20 mg and 30 mg. ...

Non-safety-related voluntary market withdrawal of a limited portion of DAYTRANA(R) (methylphenidate transdermal system) patches announced

.../recall of thirty-nine (39) lots of the ADHD patch daytrana (the lots of daytrana patches affected by this action are listed below). Shire is taking this action because some daytrana patches no longer meet their release liner removal...

Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track

... 10.6(3) n/a n/a 2% daytrana 9.4 -5% 64% ...to be recognized into revenue by the end of 2007. daytrana - ADHD DAYTRANA's average share of the US ADHD ma...the US ADHD market resulted in US prescriptions of daytrana for the three months to September 30, 2007 being u...

Shire to Present New Scientific Data on its ADHD Treatments at a Major Psychiatric Meeting

...e Effect Size in Children with ADHD Poster# E58 daytrana (methylphenidate transdermal system): October 25...Information go to http://www.vyvanse.com . About daytrana Tell your doctor about any heart conditions, incl...t heart problems, such as chest pain or fainting. daytrana should not be used if the child has: significant a...
Daytrana in Medical Technology

Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)

...m) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). A request from European regulators to conduct an additional clinical study on daytrana in a European patient population combined with the recently announced planned acquisition of the worldwide rights (excluding the US, Canada and Barbad...

New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months

...D). The findings from the analysis reaffirmed that daytrana has an established safety profile and effectively ...n, D.C. "This analysis further demonstrates that daytrana has a recognized safety profile and is an effectiv... decreased weight. In the study, the efficacy of daytrana was measured using the ADHD Rating Scale (ADHD-RS-...

Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)

...ractivity Disorder (ADHD) patch, demonstrated that daytrana provided significant ADHD tolerability and symptom...ective ADHD symptom control improvement when using daytrana for 12 months, improving their ability to maintain...a. "Importantly, this year- long study showed that daytrana maintained a favorable safety profile throughout t...

Shire to Present New Scientific Data on ADHD Treatment Portfolio at APA Annual Meeting

...ctivity Disorder APA Poster# NR750 daytrana (methylphenidate transdermal system): May 23...tite, insomnia, headache, and weight loss. About daytrana daytrana should not be used in patients with allergy to met...

12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA (methylphenidate transdermal system)

...D experienced effective ADHD treatment with use of daytrana for 12 months, sustaining the improvements in thei... Pittsburgh School of Medicine. "More importantly, daytrana maintained a favorable safety profile, meeting the... and other stimulants in this class." Shire's daytrana is the first and only patch medication approved by...

Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls

...agnosed and, therefore, undertreated. Shire's daytrana is the first and only patch medication approved by...e symptoms of ADHD in children aged 6 to 12 years. daytrana is available in four dosage strengths - 10 mg, 15 ...dy's primary endpoint. The 58 boys that received daytrana averaged a significant 56 percent ADHD- RS-IV tota...
Daytrana in Biological Technology

Shire plc: Core Portfolio of Products Delivers 20% Sales Growth

... 67.4 -77% -77% -48% 11.0% daytrana 14.9 -34% -34% ...ADDERALL XR to Teva in the URA calculation. daytrana - ADHD Product sales of daytrana for the three months to June 30, 2009 decreased by...

Shire begins the year with a strong performance

...-promotion of LIALDA in the US. Pipeline daytrana - for the treatment of ADHD in children in the EU ...he MAA does not impact Shire's commitment to daytrana in the US where the product has been used as...the US in the fourth quarter of 2009; - daytrana for the treatment of ADHD in adolescents in the US...

Publication of Shire plc's Annual Report 2008

...VANT in certain EU countries; - the launch of daytrana (EU and Canada); - the continued roll out of ...oval; six in the US (FOSRENOL and EQUETRO in 2004, daytrana and ELAPRASE in 2006, LIALDA and VYVANSE in 2007) ...atory filing for VYVANSE in Europe in 2010. daytrana for ADHD in EU & Canada Regulatory subm...

Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion

...ucting additional clinical outcomes trials; - daytrana (methylphenidate transdermal system) for use in th... 318.9 +317% +388% 8.2% daytrana 78.7 +23% -11% ...n 2007) and a price increase in April 2008. daytrana - ADHD Product sales for the year to Decemb...

Shire's New Product Portfolio Delivers Strong Quarterly Performance

... 96.0 806% n/a 9.0% daytrana 18.1 93% -14% ... of 10.2%, based on weekly prescription volumes. daytrana - ADHD Product sales for the three months to Sep... of DAYTRANA. No interruption in the production of daytrana is anticipated. Shire and Noven may take additiona...

Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade.

... 65.2 n/a n/a 7.4% daytrana 22.6 14% -11% ...re of 8.2% based on weekly prescription volumes. daytrana - ADHD Product sales for the three months to Jun...nounced a voluntary recall of a limited portion of daytrana patches because certain patches did not meet their...

Non-Safety-Related Voluntary Recall of a Limited Portion of DAYTRANA(TM) (Methylphenidate Transdermal System) Patches Announced

...voluntary recall of two (2) lots of the ADHD patch daytrana (lots 2750211 and 2764111). Shire is taking this a...while being opened. The current supply levels of daytrana should be sufficient to ensure that patients can continue to have their daytrana prescriptions filled at their local pharmacy. Nove...

Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance

...have difficulty removing the release liner of some daytrana patches, similar to the concerns which led to a voluntary market withdrawal of a limited number of daytrana patches in September 2007. Shire and Noven continu...for use in adult patients in the US in Q2 2008; - daytrana in the EU during H1 2009; - INTUNIV in the US dur...

Shire plc: IFRS Results for the Year Ending December 31, 2007

... 76.5 - N/A N/A daytrana 64.2 25.1 +156 +...to revenue during the year to December 31, 2007. daytrana - ADHD Product sales for the year to December 31...NA was launched in June 2006). US prescriptions of daytrana for the year to December 31, 2007 over 2006 benefi...

Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%

...nto new geographies. These products, together with daytrana that was launched last year, represented 32% of ou... patients, of which 7.5 million are untreated. - daytrana - ADHD - Regulatory submissions were filed for app...US in Q2 2008 (PDUFA date April 28, 2008); - daytrana in the EU during H1 2009; - INTUNIV in the US dur...
Other Tags
(Date:7/29/2014)... Colorado (PRWEB) July 29, 2014 Daily ... that the program was actually created by a popular ... too. He tried numerous treatments for this disorder, but ... found himself in the situation of having to look ... years of research. Dawson used this method, too, to ...
(Date:7/29/2014)... Advertising claims for cosmetic procedures using stem cells ... safety and effectiveness, according to a review in the ... , the official medical journal of the ... cells offer tremendous potential, but the marketplace is saturated ... patients at risk," write Dr Michael T. Longaker of ...
(Date:7/29/2014)... Angeles, CA (PRWEB) July 29, 2014 ... the website of Time Magazine titled “From Kim’s Butt ... Kim Kardashian’s butt is the celebrity feature ... and their features include Beyoncé’s butt, Jennifer Lawrence’s ... lips. This information is based on data collected by ...
(Date:7/29/2014)... 29, 2014 Tylenol lawsuits ( ... allegedly suffered serious liver injuries due to the ... in a multidistrict litigation underway in U.S. District ... reports. According to an Order dated July 23rd, ... to bellwether case and discovery issues. Among other ...
(Date:7/29/2014)... Avenidas is always looking for ... again, the non-profit agency is doing just that with the ... , This event gives seniors the opportunity to learn about ... will be a variety of fun activities, including a Tai ... and artists. In addition, there will be food tastings, courtesy ...
Breaking Medicine News(10 mins):Health News:Natural Vitiligo Treatment System Review Reveals Michael Dawson’s New Vitiligo Cure Program 2Health News:Beware of claims about cosmetic stem cells procedures, says review in Plastic and Reconstructive Surgery 2Health News:Celebrity Plastic Surgery: Kim Kardashian’s Butt Tops the List of Celebrity Plastic Surgery Requests 2Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 4Health News:Avenidas Hosts Third Annual Successful Aging Celebration 2
(Date:7/29/2014)... San Francisco is the first to show that while ... cellular aging, these negative effects may be reduced by ... , "The study participants who exercised, slept well and ... who didn,t maintain healthy lifestyles, even when they had ... PhD, assistant professor in the department of psychiatry at ...
(Date:7/28/2014)... people in the United States have a circulatory problem ... be painful and may even require surgery in serious ... wasting and, in turn, limb amputation. , At The ... Medical School, scientists tested a non-surgical preventative treatment in ... associated with increased blood circulation. Their proof-of-concept study ...
(Date:7/28/2014)... genome of Solanum pennellii , a wild relative ... international group of researchers including the labs headed by ... Davis Department of Plant Biology. The new genome information ... The work, published July 27 in the journal ... colleagues at Aachen University in Germany. The UC Davis ...
Breaking Biology News(10 mins):Healthy lifestyle may buffer against stress-related cell aging, study says 2Scientists discover genetic switch that can prevent peripheral vascular disease in mice 2
Other Contents